{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T11:12:50Z","timestamp":1793445170690,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T00:00:00Z","timestamp":1679961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T00:00:00Z","timestamp":1679961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ital J Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Invasive pulmonary aspergillosis (IPA) is a severe condition in immunocompromised children, but the optimal management is still under debate. In order to better clarify this issue, a literature search was performed through MEDLINE\/PubMed database to describe current risk factors and diagnostic, therapeutic and prophylactic tools for invasive pulmonary aspergillosis (IPA) in the paediatric age. Observational studies and clinical trials regarding diagnosis, treatment and prophylaxis were considered, and results were summarised. Five clinical trials and 25 observational studies (4453 patients) were included.<\/jats:p><jats:p>Haematological malignancies, previous organ transplant and other primary or acquired immunodeficiency were identified as risk factors for IPA in children.<\/jats:p><jats:p>Current diagnostic criteria distinguish between \"proven\", \"probable\" and \"possible\" disease. Consecutive galactomannan assays have good sensitivity and specificity, especially when performed on broncho-alveolar lavage. At the same time, \u03b2-D-glucan should not be used since cut-off in children is unclear. PCR assays cannot currently be recommended for routine use.<\/jats:p><jats:p>Voriconazole is the recommended first-line agent for IPA in children older than 2\u00a0years of age. Liposomal amphotericin B is preferred in younger patients or cases of intolerance to voriconazole. Its plasma concentrations should be monitored throughout the treatment. The optimal duration of therapy has yet to be determined. Posaconazole is the preferred prophylactic agent in children older than 13\u00a0years old, whereas oral voriconazole or itraconazole are the drugs of choice for those between 2\u201312\u00a0years. Further good-quality studies are warranted to improve clinical practice.\n<\/jats:p>","DOI":"10.1186\/s13052-023-01440-9","type":"journal-article","created":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T06:02:37Z","timestamp":1679983357000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Management of pulmonary aspergillosis in children: a systematic review"],"prefix":"10.1186","volume":"49","author":[{"given":"Vito","family":"Terlizzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco Antonio","family":"Motisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Pellegrino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Galli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Taccetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1476-4752","authenticated-orcid":false,"given":"Elena","family":"Chiappini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,28]]},"reference":[{"key":"1440_CR1","first-page":"211","volume":"2021","author":"D Kimberlin","year":"2021","unstructured":"Kimberlin D, Barnett ED, Lynfield R, American SMH, Academy of Pediatrics. Aspergillosis. Red Book. Red Book,. Report of the Commitee on Infectious Disease. Itasca. 2021;2021:211\u20135.","journal-title":"Itasca"},{"key":"1440_CR2","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/pai.13357","volume":"31","author":"S Manti","year":"2020","unstructured":"Manti S, Parisi GF, Papale M, Licari A, Chiappini E, Mul\u00e8 E, et al. Allergic bronchopulmonary aspergillosis in children. Pediatr Allergy Immunol. 2020;31:20\u20132.","journal-title":"Pediatr Allergy Immunol"},{"key":"1440_CR3","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","DOI":"10.1136\/bmj.n71"},{"key":"1440_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1\u201312.","journal-title":"Control Clin Trials"},{"key":"1440_CR5","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","volume":"73","author":"K Slim","year":"2003","unstructured":"Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73:712\u20136.","journal-title":"ANZ J Surg"},{"key":"1440_CR6","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet Elsevier. 2007;370:1453\u20137.","journal-title":"Lancet Elsevier"},{"key":"1440_CR7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3389\/fped.2018.00031","volume":"6","author":"N Anantasit","year":"2018","unstructured":"Anantasit N, Nuntacharruksa N, Incharoen P, Preutthipan A. Clinical and Pathological Correlation in Pediatric Invasive Pulmonary Aspergillosis. Front Pediatr. 2018;6:31.","journal-title":"Front Pediatr"},{"key":"1440_CR8","first-page":"8","volume":"54","author":"G Avcu","year":"2017","unstructured":"Avcu G, Karapinar DY, Akinci AB, Sivis ZO, Sahin A, Bal ZS, et al. Utility of the serum galactomannan assay for the diagnosis of invasive aspergillosis in children with acute lymphoblastic leukemia. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2017;54:8\u201312.","journal-title":"Int J Infect Dis IJID Off Publ Int Soc Infect Dis"},{"key":"1440_CR9","doi-asserted-by":"publisher","first-page":"352","DOI":"10.3855\/jidc.2110","volume":"6","author":"P Badiee","year":"2012","unstructured":"Badiee P, Alborzi A, Karimi M, Pourabbas B, Haddadi P, Mardaneh J, et al. Diagnostic potential of nested PCR, galactomannan EIA, and beta-D-glucan for invasive aspergillosis in pediatric patients. J Infect Dev Ctries. 2012;6:352\u20137.","journal-title":"J Infect Dev Ctries"},{"key":"1440_CR10","doi-asserted-by":"publisher","first-page":"e1286","DOI":"10.1542\/peds.2007-2117","volume":"121","author":"A Burgos","year":"2008","unstructured":"Burgos A, Zaoutis TE, Dvorak CC, Hoffman JA, Knapp KM, Nania JJ, et al. Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary cases. Pediatrics. 2008;121:e1286-1294.","journal-title":"Pediatrics"},{"key":"1440_CR11","doi-asserted-by":"publisher","first-page":"e271","DOI":"10.1097\/MPH.0000000000001653","volume":"42","author":"\u0130 \u00c7a\u011flar","year":"2020","unstructured":"\u00c7a\u011flar \u0130, \u00d6zkerim D, Tahta N, D\u00fczg\u00f6l M, Bayram N, Demira\u011f B, et al. Assessment of Serum Galactomannan Test Results of Pediatric Patients With Hematologic Malignancies According to Consecutive Positivity and Threshold Level in Terms of Invasive Aspergillosis Diagnosis: Cross-Sectional Research in a Tertiary Care Hospital. J Pediatr Hematol Oncol. 2020;42:e271\u20136.","journal-title":"J Pediatr Hematol Oncol"},{"key":"1440_CR12","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1002\/pbc.24363","volume":"60","author":"S-H Choi","year":"2013","unstructured":"Choi S-H, Kang E-S, Eo H, Yoo S-Y, Kim JH, Yoo KH, et al. Aspergillus galactomannan antigen assay and invasive aspergillosis in pediatric cancer patients and hematopoietic stem cell transplant recipients. Pediatr Blood Cancer. 2013;60:316\u201322.","journal-title":"Pediatr Blood Cancer"},{"key":"1440_CR13","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/ppul.22670","volume":"48","author":"M de Mol","year":"2013","unstructured":"de Mol M, de Jongste JC, van Westreenen M, Merkus PJFM, de Vries AHC, Hop WCJ, et al. Diagnosis of invasive pulmonary aspergillosis in children with bronchoalveolar lavage galactomannan. Pediatr Pulmonol. 2013;48:789\u201396.","journal-title":"Pediatr Pulmonol"},{"key":"1440_CR14","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jmii.2013.12.003","volume":"49","author":"V Dinand","year":"2016","unstructured":"Dinand V, Anjan M, Oberoi JK, Khanna S, Yadav SP, Wattal C, et al. Threshold of galactomannan antigenemia positivity for early diagnosis of invasive aspergillosis in neutropenic children. J Microbiol Immunol Infect Wei Mian Yu Gan Ran Za Zhi. 2016;49:66\u201373.","journal-title":"J Microbiol Immunol Infect Wei Mian Yu Gan Ran Za Zhi"},{"key":"1440_CR15","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/1471-2334-12-151","volume":"12","author":"M D\u00f6ring","year":"2012","unstructured":"D\u00f6ring M, Hartmann U, Erbacher A, Lang P, Handgretinger R, M\u00fcller I. Caspofungin as antifungal prophylaxis in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective analysis. BMC Infect Dis. 2012;12:151.","journal-title":"BMC Infect Dis"},{"key":"1440_CR16","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1007\/s10096-015-2340-y","volume":"34","author":"M D\u00f6ring","year":"2015","unstructured":"D\u00f6ring M, Eikemeier M, Cabanillas Stanchi KM, Hartmann U, Ebinger M, Schwarze C-P, et al. Antifungal prophylaxis with posaconazole vs fluconazole or itraconazole in pediatric patients with neutropenia. Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol. 2015;34:1189\u2013200.","journal-title":"Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol."},{"key":"1440_CR17","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/jpids\/pis044","volume":"1","author":"BT Fisher","year":"2012","unstructured":"Fisher BT, Zaoutis TE, Park JR, Bleakley M, Englund JA, Kane C, et al. Galactomannan Antigen Testing for Diagnosis of Invasive Aspergillosis in Pediatric Hematology Patients. J Pediatr Infect Dis Soc. 2012;1:103\u201311.","journal-title":"J Pediatr Infect Dis Soc"},{"key":"1440_CR18","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1001\/jama.2019.15702","volume":"322","author":"BT Fisher","year":"2019","unstructured":"Fisher BT, Zaoutis T, Dvorak CC, Nieder M, Zerr D, Wingard JR, et al. Effect of Caspofungin vs Fluconazole Prophylaxis on Invasive Fungal Disease Among Children and Young Adults With Acute Myeloid Leukemia: A Randomized Clinical Trial. JAMA. 2019;322:1673\u201381.","journal-title":"JAMA"},{"key":"1440_CR19","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1093\/jpids\/piab036","volume":"10","author":"BT Fisher","year":"2021","unstructured":"Fisher BT, Westling T, Boge CLK, Zaoutis TE, Dvorak CC, Nieder M, et al. Prospective Evaluation of Galactomannan and (1\u21923) \u03b2-d-Glucan Assays as Diagnostic Tools for Invasive Fungal Disease in Children, Adolescents, and Young Adults With Acute Myeloid Leukemia Receiving Fungal Prophylaxis. J Pediatr Infect Dis Soc. 2021;10:864\u201371.","journal-title":"J Pediatr Infect Dis Soc"},{"key":"1440_CR20","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3109\/08880018.2014.981900","volume":"32","author":"A Gefen","year":"2015","unstructured":"Gefen A, Zaidman I, Shachor-Meyouhas Y, Avidor I, Hakim F, Weyl Ben-Arush M, et al. Serum galactomannan screening for diagnosis of invasive pulmonary aspergillosis in children after stem cell transplantation or with high-risk leukemia. Pediatr Hematol Oncol. 2015;32:146\u201352.","journal-title":"Pediatr Hematol Oncol"},{"key":"1440_CR21","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.3346\/jkms.2015.30.8.1121","volume":"30","author":"SB Han","year":"2015","unstructured":"Han SB, Kim SK, Bae EY, Lee JW, Yoon J-S, Chung N-G, et al. Clinical Features and Prognosis of Invasive Pulmonary Aspergillosis in Korean Children with Hematologic\/Oncologic Diseases. J Korean Med Sci. 2015;30:1121\u20138.","journal-title":"J Korean Med Sci"},{"key":"1440_CR22","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa020191","volume":"347","author":"R Herbrecht","year":"2002","unstructured":"Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann J-W, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347:408\u201315.","journal-title":"N Engl J Med"},{"key":"1440_CR23","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1016\/j.transproceed.2021.04.010","volume":"53","author":"S Itsaradisaikul","year":"2021","unstructured":"Itsaradisaikul S, Pakakasama S, Boonsathorn S, Techasaensiri C, Rattanasiri S, Apiwattanakul N. Invasive Fungal Disease Among Pediatric and Adolescent Patients Undergoing Itraconazole Prophylaxis After Hematopoietic Stem Cell Transplantation. Transplant Proc. 2021;53:2021\u20138.","journal-title":"Transplant Proc"},{"key":"1440_CR24","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/myc.12048","volume":"56","author":"AK Jha","year":"2013","unstructured":"Jha AK, Bansal D, Chakrabarti A, Shivaprakash MR, Trehan A, Marwaha RK. Serum galactomannan assay for the diagnosis of invasive aspergillosis in children with haematological malignancies. Mycoses. 2013;56:442\u20138.","journal-title":"Mycoses"},{"key":"1440_CR25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jiac.2015.09.008","volume":"22","author":"K Kato","year":"2016","unstructured":"Kato K, Nagao M, Yamamoto M, Matsumura Y, Takakura S, Fukuda K, et al. Oral administration and younger age decrease plasma concentrations of voriconazole in pediatric patients. J Infect Chemother Off J Jpn Soc Chemother. 2016;22:27\u201331.","journal-title":"J Infect Chemother Off J Jpn Soc Chemother"},{"key":"1440_CR26","first-page":"37","volume":"6","author":"N Kazakou","year":"2020","unstructured":"Kazakou N, Vyzantiadis TA, Gambeta A, Vasileiou E, Tsotridou E, Kotsos D, et al. Invasive fungal infections in a pediatric hematology-oncology department: A 16-year retrospective study. Curr Med Mycol. 2020;6:37\u201342.","journal-title":"Curr Med Mycol"},{"key":"1440_CR27","doi-asserted-by":"publisher","first-page":"167","DOI":"10.5045\/br.2017.52.3.167","volume":"52","author":"KH Lee","year":"2017","unstructured":"Lee KH, Lim YT, Hah JO, Kim YK, Lee CH, Lee JM. Voriconazole plus caspofungin for treatment of invasive fungal infection in children with acute leukemia. Blood Res. 2017;52:167\u201373.","journal-title":"Blood Res"},{"key":"1440_CR28","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1128\/JCM.01682-16","volume":"55","author":"J Loeffler","year":"2017","unstructured":"Loeffler J, Hafner J, Mengoli C, Wirth C, Heussel CP, L\u00f6ffler C, et al. Prospective Biomarker Screening for Diagnosis of Invasive Aspergillosis in High-Risk Pediatric Patients. J Clin Microbiol. 2017;55:101\u20139.","journal-title":"J Clin Microbiol"},{"key":"1440_CR29","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1097\/INF.0b013e3181da2171","volume":"29","author":"JA Maertens","year":"2010","unstructured":"Maertens JA, Madero L, Reilly AF, Lehrnbecher T, Groll AH, Jafri HS, et al. A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia. Pediatr Infect Dis J. 2010;29:415\u201320.","journal-title":"Pediatr Infect Dis J"},{"key":"1440_CR30","doi-asserted-by":"publisher","first-page":"e451","DOI":"10.1097\/INF.0b013e3182a74233","volume":"32","author":"GM Maron","year":"2013","unstructured":"Maron GM, Hayden RT, Rodriguez A, Rubnitz JE, Flynn PM, Shenep JL, et al. Voriconazole prophylaxis in children with cancer: changing outcomes and epidemiology of fungal infections. Pediatr Infect Dis J. 2013;32:e451-455.","journal-title":"Pediatr Infect Dis J"},{"key":"1440_CR31","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1097\/INF.0000000000001339","volume":"36","author":"JM Martin","year":"2017","unstructured":"Martin JM, Macias-Parra M, Mudry P, Conte U, Yan JL, Liu P, et al. Safety, Efficacy, and Exposure-Response of Voriconazole in Pediatric Patients With Invasive Aspergillosis, Invasive Candidiasis or Esophageal Candidiasis. Pediatr Infect Dis J. 2017;36:e1-13.","journal-title":"Pediatr Infect Dis J"},{"key":"1440_CR32","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1093\/mmy\/myv053","volume":"53","author":"S Mohammadi","year":"2015","unstructured":"Mohammadi S, Khalilzadeh S, Goudarzipour K, Hassanzad M, Mahdaviani A, Aarabi N, et al. Bronchoalveolar galactomannan in invasive pulmonary aspergillosis: a prospective study in pediatric patients. Med Mycol. 2015;53:709\u201316.","journal-title":"Med Mycol"},{"key":"1440_CR33","doi-asserted-by":"publisher","first-page":"e13641","DOI":"10.1111\/ctr.13641","volume":"33","author":"K-Y Qiu","year":"2019","unstructured":"Qiu K-Y, Liao X-Y, Huang K, Xu H-G, Li Y, Fang J-P, et al. The early diagnostic value of serum galactomannan antigen test combined with chest computed tomography for invasive pulmonary aspergillosis in pediatric patients after hematopoietic stem cell transplantation. Clin Transplant. 2019;33:e13641.","journal-title":"Clin Transplant"},{"key":"1440_CR34","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.clinthera.2018.05.002","volume":"40","author":"G Vrioni","year":"2018","unstructured":"Vrioni G, Theodoridou K, Tsiamis C, Mavrouli M, Kapsimali V, Rigopoulos D, et al. Use of Galactomannan Antigen and Aspergillus DNA Real-time Polymerase Chain Reaction as Routine Methods for Invasive Aspergillosis in Immunosuppressed Children in Greece. Clin Ther. 2018;40:918-924.e2.","journal-title":"Clin Ther"},{"key":"1440_CR35","doi-asserted-by":"publisher","first-page":"e711","DOI":"10.1542\/peds.2005-1161","volume":"117","author":"TE Zaoutis","year":"2006","unstructured":"Zaoutis TE, Heydon K, Chu JH, Walsh TJ, Steinbach WJ. Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000. Pediatrics. 2006;117:e711-716.","journal-title":"Pediatrics"},{"key":"1440_CR36","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","volume":"71","author":"JP Donnelly","year":"2020","unstructured":"Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, et al. Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2020;71:1367\u201376.","journal-title":"Clin Infect Dis"},{"key":"1440_CR37","doi-asserted-by":"publisher","first-page":"220011","DOI":"10.1183\/16000617.0011-2022","volume":"31","author":"S Manti","year":"2022","unstructured":"Manti S, Giallongo A, Parisi GF, Papale M, Mul\u00e8 E, Aloisio D, et al. Biologic drugs in treating allergic bronchopulmonary aspergillosis in patients with cystic fibrosis: a systematic review. Eur Respir Rev Off J Eur Respir Soc. 2022;31:220011.","journal-title":"Eur Respir Rev Off J Eur Respir Soc"},{"key":"1440_CR38","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1128\/AAC.00454-06","volume":"51","author":"G Krishna","year":"2007","unstructured":"Krishna G, Sansone-Parsons A, Martinho M, Kantesaria B, Pedicone L. Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. Antimicrob Agents Chemother. 2007;51:812\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"1440_CR39","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1046\/j.1365-2141.1997.2473063.x","volume":"98","author":"HG Prentice","year":"1997","unstructured":"Prentice HG, Hann IM, Herbrecht R, Aoun M, Kvaloy S, Catovsky D, et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol. 1997;98:711\u20138.","journal-title":"Br J Haematol"}],"container-title":["Italian Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13052-023-01440-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13052-023-01440-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13052-023-01440-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T06:06:31Z","timestamp":1679983591000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijponline.biomedcentral.com\/articles\/10.1186\/s13052-023-01440-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,28]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1440"],"URL":"https:\/\/doi.org\/10.1186\/s13052-023-01440-9","relation":{},"ISSN":["1824-7288"],"issn-type":[{"value":"1824-7288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,28]]},"assertion":[{"value":"4 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing of interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39"}}